Abstract P6-07-44: Overall survival and the prognostic factors among women with infiltrating lobular carcinoma of the breast in National Cancer Institute of Brazil
Authors: Bello MA , Monteiro SO , Lima DT , Gomes DO , Thuler LCS , Carmo PAO , Carvalho RM , Pinto RR , Bergmann A 
Published: August 2014

Abstract
BACKGROUND: The infiltrating lobular carcinoma (ILC) comprises approximately 10% of breast cancers and appears to have a distinct biology. Because it is less common than infiltrating ductal carcinoma (IDC), there are less data published regarding about their clinical outcomes. This study estimates survival rates in women with infiltrating lobular carcinoma of the breast, diagnosed between 2000 to 2009 that had undergone treatment in the National Cancer Institute of Brazil.
OBJECTIVES: Analyze overall survival and the main prognostic factors among women with infiltrating lobular carcinoma of the breast, diagnosed from 2000 to 2009 that had undergone treatment in the National Cancer Institute of Brazil.
MATERIALS AND METHODS: The survival curves were obtained in a hospital cohort of 843 patients with infiltrating lobular carcinoma of the breast diagnosed and treated between 2000 to 2009. The study variables were: age, race, tobacco, alcohol consumption, tumor-related variables, and treatment-related variables. Survival functions were calculated by the Kaplan-Meier method.
RESULTS: The mean follow up time was 64,27 months (sd 33,76), with 30,2% of deaths occurred in the period where the mean patients age was 58,58 years (sd 13,22). The overall survival (OS) was 105,61 months (95% CI, 101,68 to 109,54). The OS for patients with 4 or more positives axillary lymph nodes was 91,66 months (95% CI, 83,19 to 100,13; p &lt; 0,0001) worse than patients with no positive axillary lymph node, where the overall survival was 124,26 months (95% CI, 119,41 to 129,12; p &lt; 0.0001). The OS in patients with estrogen receptor positive was 109,05 months (95% IC, 104,83 to 113,28; p &lt; 0.001) whereas in patients with hormone estrogen receptor negative, the OS was 81,75 months (95% CI, 69,93 to 93,58; p &lt; 0,0001). Among smokers patients, the OS was 97,46 months (95% CI, 90,80 to 104,12; p = 0,012) and for no smoking patients, the OS was109,01 months (95% CI, 104,24 to113,79; p = 0,012). Patients in stage 1 and 2 show an mean overall survival of 126,76 months (95% CI, 122,77 to130,75; p &lt; 0.0001) and patients in stage 3 and 4 show a worse overall survival with mean 74,61 months (95% CI, 68,59 to 80,62; p &lt; 0.0001). The patients younger than 40 years old had worse overall survival, with mean 88,88 months (95% C, 72,98 to 104,72; p = 0.032) than those with more than 40 years old, where the mean was 106,77 months (95% CI, 102,74 to 110,79; p = 0,032). The consumption of alcoholic beverages and pleomorphic histological variant showed no statistically significant difference in overall survival.
CONCLUSION: The mean follow up time was 64,27 months with 30,2% of deaths occurred in the period. The overall survival (OS) was 105,61 months. The OS was asssociated with axillary involvement, estrogen and progesterone receptor hormone, age and tobacco.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-07-44.